Amgen Reports Ten-Year FREEDOM Extension Data for Prolia in Postmenopausal Osteoporosis

Amgen today presented ten-year follow-up data from the FREEDOM extension study evaluating Prolia (denosumab) in postmenopausal women with osteoporosis. The data showed that Prolia maintained significant improvements in bone mineral density and continued to reduce fracture risk over ten years of treatment. The safety profile remained consistent with previous observations.